Aligos Therapeutics (ALGS) has filed a preliminary prospectus for a $100M IPO.

The South San Francisco, CA-based biopharmaceutical company leverages its oligonucleotide and small molecule platforms to develop drugs for use in combo regimens for viral and liver diseases. Lead program, comprised of four candidates, is aimed at a functional cure for chronic hepatitis B virus (HBV) infection. Another program, with one candidate at present, is focused on NASH, currently preclinical.

2020 Financials (6 mo.): Operating Expenses: $42.0M (+99%); Net Loss: ($40.8M) (-104%); Cash Burn: ($38.0M) (-108%).


Source link

Comments to: Aligos Therapeutics preparing $100M IPO (Pending:ALGS)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.